EHA 2024 | Results from a Phase II trial of pirtobrutinib, venetoclax, and obinutuzumab in CLL
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the results from a Phase II (NCT05536349) study of front-line pirtobrutinib, venetoclax, and obinutuzumab in 40 patients with chronic lymphocytic leukemia (CLL). Measurable residual disease (MRD) in both the bone marrow and peripheral blood was undetectable in a large proportion of patients after 6 and 12 months of therapy, indicating a deep remission. The rate of neutropenia was comparable to that reported in previous studies. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
